Memantine Hydrochloride Genus (Memantine Hydrochloride)

Memantine Hydrochloride is used in the management of neurodegenerative conditions affecting the glutamatergic pathway, primarily Alzheimer’s disease.

• Alzheimer's disease (moderate to severe): improves cognition and functional abilities in adult patients.
• Dementia associated with Alzheimer’s disease (moderate to severe): helps maintain daily living activities and slows functional decline.
• Cognitive decline in Alzheimer’s disease: may provide modest benefit in memory and executive function.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel with moderate affinity, it reduces excessive calcium influx caused by prolonged glutamate activation. This moderates excitotoxic neuronal injury and stabilises synaptic transmission, while preferentially blocking pathological over‑activation and preserving normal physiological NMDA activity, allowing essential neurotransmission to continue.

Memantine Hydrochloride may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Dizziness
• Headache
• Constipation
• Fatigue

Serious or Rare Side Effects

• Seizures
• Cardiac arrhythmia
• Severe allergic reaction (anaphylaxis)

When prescribing Memantine Hydrochloride, clinicians should consider several safety factors.

• Renal impairment: dose adjustment may be required; monitor renal function.
• History of seizures: use with caution and monitor for increased seizure activity.
• Cardiovascular disease: assess blood pressure and heart rate regularly.
• Concomitant use with other NMDA antagonists: avoid due to additive neurotoxicity risk.
• Pregnancy: safety not established; avoid unless benefits outweigh risks.
• Store at room temperature: keep in original packaging, protect from moisture and light.

Memantine Hydrochloride can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism may increase neurotoxicity.
• Other NMDA receptor antagonists (e.g., ketamine): additive CNS effects.

Moderate Interactions (Monitor Closely)

• Anticholinesterase inhibitors (donepezil, rivastigmine): monitor for synergistic cognitive effects.
• Diuretics (e.g., furosemide): may enhance hypotensive effect.
• CNS depressants (benzodiazepines, alcohol): monitor for increased sedation.
• Antihypertensive agents: monitor blood pressure.